Fallah MP, Wayengera M, Adewole IF, Dereje N, Temfack E, Bamatura M, Tabaro CA, Shaweno T, Duga A, Kuonza F, Tekle BI, Kisera N, Mesfin AA, Osman SOS, Wasunna M, Nyansulu PS, Ogutu B, Adu-Sarkodie Y, N’jai AU, Rashid A, Nyan DC, Mangu C, Raji T, Mbala P, Muyembe JJ, Sewankambo N, Kaseya J. Nature Medicine 2026. doi:10.1038/s41591-026-04480-w
Summary: Africa’s vulnerability during health emergencies, such as the COVID-19 pandemic and Ebola outbreaks, highlights the risks of dependence on imported vaccines, diagnostics, and therapeutics. The authors of this comment argue for a transition from externally driven research toward continent-led, regionally coordinated R&D hubs integrating basic science, translational research, clinical development, and local manufacturing. Drawing on capacity built through decades of infectious disease research, international partnerships, and initiatives such as the H3Africa Consortium, they propose a shift from episodic, outbreak-driven research activity toward purposeful, market-aware investment in regional R&D hubs. The authors conclude that the historical inequality in R&D must be addressed if Africa is to be sustainably self-reliant and to eventually contribute to global health and economic security.
